Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease

Human Molecular Genetics

Volumn 19, Issue 19, 2010, Pages 3771-3781

  Ron, Idit ^a   Rapaport, Debora ^a   Horowitz, Mia ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; MUTANT PROTEIN; PARKIN; PROTEASOME; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CELL STRAIN HEK293; CONTROLLED STUDY; DISEASE SEVERITY; ENDOPLASMIC RETICULUM; GAUCHER DISEASE; GENE; HUMAN; HUMAN CELL; NONHUMAN; PARK2 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

ANIMALS; CELL LINE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; LYSINE; MUTANT PROTEINS; PARKINSON DISEASE; POLYUBIQUITIN; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 77956537090     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq292     Document Type: Article

References (88)

1. Beutler, E. (1995) Gaucher disease. In Hall, J.C. and Dunlap, J.C. (eds), Advances in Genetics. Academic Press, Inc., San Diego, CA, Vol. 32, pp. 17-49.
2. Beutler, E. and Grabowski, G.A. (2001) Gaucher disease. In Scriver, C.R., Sly, W.S., Childs, B., Beaudet, A.L., Valle, D., Kinzler and Vogelstein, K.W. (eds), The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, Inc., New York, NY, Vol. II, pp. 3635-3668.
3. Grabowski, G.A. (2001) Lysosomal storage diseases. In Braunwald, E. and Fauci, A.S. (eds), Harrison's Principles of Internal Medicine, 15th edn. McGraw-Hill, Inc., New York, NY, pp. 2276-2281.
4. Brady, R.O., Kanfer, J.N. and Shapiro, D. (1965) Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun., 18, 221-225.
5. Ron, I. and Horowitz, M. (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet., 14, 2387-2398.
6. Bonifacino, J.S. and Weissman, A.M. (1998) Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu. Rev. Cell. Dev. Biol., 14, 19-57.
7. Brodsky, J.L. and McCracken, A.A. (1999) ER protein quality control and proteasome-mediated protein degradation. Semin. Cell. Dev. Biol., 10, 507-513.
8. Kopito, R.R. (1997) ER quality control: the cytoplasmic connection. Cell, 88, 427-430.
9. Ciechanover, A. (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J., 17, 7151-7160.
10. Ciechanover, A. (2001) Linking ubiquitin, parkin and synphilin-1. Nat. Med., 7, 1108-1109.
11. Ciechanover, A. and Schwartz, A.L. (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc. Natl Acad. Sci. USA, 95, 2727-2730.
12. Haas, A.L., Warms, J.V., Hershko, A. and Rose, I.A. (1982) Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem., 257, 2543-2548.
13. Hershko, A. and Ciechanover, A. (1998) The ubiquitin system. Annu. Rev. Biochem., 67, 425-479.
14. Pickart, C.M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. Biochem., 70, 503-533.
15. Pickart, C.M. and Fushman, D. (2004) Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol., 8, 610-616.
16. Haglund, K. and Dikic, I. (2005) Ubiquitylation and cell signaling. EMBO J., 24, 3353-3359.
17. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J. and Sidransky, E. (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab., 73, 313-321.
18. Tayebi, N., Walker, J., Stubblefield, B., Orvisky, E., LaMarca, M.E., Wong, K., Rosenbaum, H., Schiffmann, R., Bembi, B. and Sidransky, E. (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab., 79, 104-109.
19. Bembi, B., Zambito Marsala, S., Sidransky, E., Ciana, G., Carrozzi, M., Zorzon, M., Martini, C., Gioulis, M., Pittis, M.G. and Capus, L. (2003) Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology, 61, 99-101.
20. Aharon-Peretz, J., Rosenbaum, H. and Gershoni-Baruch, R. (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med., 351, 1972-1977.
21. Goker-Alpan, O., Schiffmann, R., LaMarca, M.E., Nussbaum, R.L., McInerney-Leo, A. and Sidransky, E. (2004) Parkinsonism among Gaucher disease carriers. J. Med. Genet., 41, 937-940.
22. Sidransky, E. (2005) Gaucher disease and parkinsonism. Mol. Genet. Metab., 84, 302-304.
23. Zimran, A., Neudorfer, O. and Elstein, D. (2005) The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med., 352, 728-731. Author reply, 728-731.
24. Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A. and Orr-Urtreger, A. (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology, 70, 2277-2283.
25. Goker-Alpan, O., Lopez, G., Vithayathil, J., Davis, J., Hallett, M. and Sidransky, E. (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol., 65, 1353-1357.
26. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A. et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med., 361, 1651-1661.
27. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. Second of two parts. N. Engl. J. Med., 339, 1130-1143.
28. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med., 339, 1044-1053.
29. Betarbet, R., Sherer, T.B. and Greenamyre, J.T. (2005) Ubiquitin- proteasome system and Parkinson's diseases. Exp. Neurol., 191(Suppl. 1), S17-S27.
30. McNaught, K.S. and Jenner, P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett., 297, 191-194.
31. Dawson, T.M. and Dawson, V.L. (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest., 111, 145-151.
32. Gasser, T. (2003) Overview of the genetics of parkinsonism. Adv. Neurol., 91, 143-152.
33. Lesage, S. and Brice, A. (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet., 18, R48-R59.
34. Warner, T.T. and Schapira, A.H. (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol., 53(Suppl. 3), S16-S23. Discussion S23-S25.
35. Imai, Y., Soda, M. and Takahashi, R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem., 275, 35661-35664.
36. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 25, 302-305.
37. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L. and Dawson, T.M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA, 97, 13354-13359.
38. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
39. Lucking, C.B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B.S., Meco, G., Denefle, P., Wood, N.W. et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med., 342, 1560-1567.
40. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y. and Takahashi, R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 105, 891-902.
41. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S. and Selkoe, D.J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263-269.
42. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med., 7, 1144-1150.
43. Staropoli, J.F., McDermott, C., Martinat, C., Schulman, B., Demireva, E. and Abeliovich, A. (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron, 37, 735-749.
44. Ren, Y., Zhao, J. and Feng, J. (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci., 23, 3316-3324.
45. Corti, O., Hampe, C., Koutnikova, H., Darios, F., Jacquier, S., Prigent, A., Robinson, J.C., Pradier, L., Ruberg, M., Mirande, M. et al. (2003) The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet., 12, 1427-1437.
46. Ko, H.S., Kim, S.W., Sriram, S.R., Dawson, V.L. and Dawson, T.M. (2006) Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J. Biol. Chem., 281, 16193-16196.
47. Tanaka, K., Suzuki, T., Hattori, N. and Mizuno, Y. (2004) Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta, 1695, 235-247.
48. Sriram, S.R., Li, X., Ko, H.S., Chung, K.K., Wong, E., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet., 14, 2571-2586.
49. Horowitz, M., Tzuri, G., Eyal, N., Berebi, A., Kolodny, E.H., Brady, R.O., Barton, N.W., Abrahamov, A. and Zimran, A. (1993) Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am. J. Hum. Genet., 53, 921-930.
50. Tsuji, S., Martin, B.M., Barranger, J.A., Stubblefield, B.K., LaMarca, M.E. and Ginns, E.I. (1988) Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc. Natl Acad. Sci. USA, 85, 2349-2352.
51. Sidransky, E. (2004) Gaucher disease: complexity in a 'simple' disorder. Mol. Genet. Metab., 83, 6-15.
52. LoPresti, P., Poluha, W., Poluha, D.K., Drinkwater, E. and Ross, A.H. (1992) Neuronal differentiation triggered by blocking cell proliferation. Cell. Growth Differ., 3, 627-635.
53. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M.E. and Sidransky, E. (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab., 81, 70-73.
54. Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M. et al. (2009) Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol., 66, 571-576.
55. Tsuji, S., Choudary, P.V., Martin, B.M., Stubblefield, B.K., Mayor, J.A., Barranger, J.A. and Ginns, E.I. (1987) A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N. Engl. J. Med., 316, 570-575.
56. Beutler, E. and Gelbart, T. (1993) Gaucher disease mutations in non-Jewish patients. Br. J. Haematol., 85, 401-405.
57. Obrig, T.G., Culp, W.J., McKeehan, W.L. and Hardesty, B. (1971) The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem., 246, 174-181.
58. Weissman, A.M. (2001) Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell. Biol., 2, 169-178.
59. Doss-Pepe, E.W., Chen, L. and Madura, K. (2005) Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J. Biol. Chem., 280, 16619-16624.
60. Lim, K.L., Chew, K.C., Tan, J.M., Wang, C., Chung, K.K., Zhang, Y., Tanaka, Y., Smith, W., Engelender, S., Ross, C.A. et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci., 25, 2002-2009.
61. Lim, K.L., Dawson, V.L. and Dawson, T.M. (2006) Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol. Aging, 27, 524-529.
62. Hampe, C., Ardila-Osorio, H., Fournier, M., Brice, A. and Corti, O. (2006) Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet., 15, 2059-2075.
63. Matsuda, N., Kitami, T., Suzuki, T., Mizuno, Y., Hattori, N. and Tanaka, K. (2006) Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J. Biol. Chem., 281, 3204-3209.
64. Junn, E., Lee, S.S., Suhr, U.T. and Mouradian, M.M. (2002) Parkin accumulation in aggresomes due to proteasome impairment. J. Biol. Chem., 277, 47870-47877.
65. Garcia-Mata, R., Gao, Y.S. and Sztul, E. (2002) Hassles with taking out the garbage: aggravating aggresomes. Traffic, 3, 388-396.
66. Johnston, J.A., Ward, C.L. and Kopito, R.R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell. Biol., 143, 1883-1898.
67. Kopito, R.R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell. Biol., 10, 524-530.
68. Olanow, C.W., Perl, D.P., DeMartino, G.N. and McNaught, K.S. (2004) Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol., 3, 496-503.
69. Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., Pastores, G. and Mistry, P.K. The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis., 33, 167-173.
70. Wang, H.Q. and Takahashi, R. (2007) Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxid. Redox. Signal., 9, 553-561.
71. Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Nakayama, K.I. and Takahashi, R. (2002) CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell, 10, 55-67.
72. Imai, Y., Soda, M., Murakami, T., Shoji, M., Abe, K. and Takahashi, R. (2003) A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J. Biol. Chem., 278, 51901-51910.
73. Choi, P., Snyder, H., Petrucelli, L., Theisler, C., Chong, M., Zhang, Y., Lim, K., Chung, K.K., Kehoe, K., D'Adamio, L. et al. (2003) SEPT5_v2 is a parkin-binding protein. Brain Res. Mol. Brain Res., 117, 179-189.
74. Ko, H.S., von Coelln, R., Sriram, S.R., Kim, S.W., Chung, K.K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E.L. et al. (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci., 25, 7968-7978.
75. Dong, Z., Ferger, B., Paterna, J.C., Vogel, D., Furler, S., Osinde, M., Feldon, J. and Bueler, H. (2003) Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc. Natl Acad. Sci. USA, 100, 12438-12443.
76. Yang, Y., Nishimura, I., Imai, Y., Takahashi, R. and Lu, B. (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron, 37, 911-924.
77. Sun, Y., Jia, L., Williams, M.T., Zamzow, M., Ran, H., Quinn, B., Aronow, B.J., Vorhees, C.V., Witte, D.P. and Grabowski, G.A. (2008) Temporal gene expression profiling reveals CEBPD as a candidate regulator of brain disease in prosaposin deficient mice. BMC Neurosci., 9, 76.
78. Schroder, M. and Kaufman, R.J. (2005) The mammalian unfolded protein response. Annu. Rev. Biochem., 74, 739-789.
79. Schroder, M. and Kaufman, R.J. (2005) ER stress and the unfolded protein response. Mutat. Res., 569, 29-63.
80. Moore, D.J., West, A.B., Dikeman, D.A., Dawson, V.L. and Dawson, T.M. (2008) Parkin mediates the degradation-independent ubiquitination of Hsp70. J. Neurochem., 105, 1806-1819.
81. Tsai, Y.C., Fishman, P.S., Thakor, N.V. and Oyler, G.A. (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem., 278, 22044-22055.
82. Dickey, C.A., Patterson, C., Dickson, D. and Petrucelli, L. (2007) Brain CHIP: removing the culprits in neurodegenerative disease. Trends Mol. Med., 13, 32-38.
83. Lowe, J., McDermott, H., Landon, M., Mayer, R.J. and Wilkinson, K.D. (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol., 161, 153-160.
84. Larsen, C.N., Krantz, B.A. and Wilkinson, K.D. (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry, 37, 3358-3368.
85. von Bohlen und Halbach, O., Schober, A. and Krieglstein, K. (2004) Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol., 73, 151-177.
86. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
87. Maraganore, D.M., Farrer, M.J., Hardy, J.A., Lincoln, S.J., McDonnell, S.K. and Rocca, W.A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology, 53, 1858-1860.
88. Healy, D.G., Abou-Sleiman, P.M. and Wood, N.W. (2004) Genetic causes of Parkinson's disease: UCHL-1. Cell. Tissue Res., 318, 189-194.